Merck KGaA's Rebif Facing Irreversible Decline, Avelumab Update Expected Soon
This article was originally published in Scrip
Executive Summary
New oral therapies for multiple sclerosis are starting to have their expected adverse effect on sales of Merck KGAA's best-selling injectable product Rebif (interferon beta-1a), whose sales markedly declined in the 2015 second quarter.